Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on September 17, 2025, reports a material financing event for Clearmind Medicine Inc., a foreign private issuer based in Vancouver, British Columbia. The filing details the execution of Securities Purchase Agreements (SPAs) with institutional investors to issue convertible promissory notes.
Key Financial Metrics and Transaction Details
- Total Potential Financing: Up to $10,000,000 in aggregate principal amount of convertible promissory notes.
- Initial Closing (First Initial Closing): $555,556 principal amount purchased for $500,000.
- Second Initial Closing: $1,944,444 principal amount to be purchased for $1,750,000 upon SEC registration effectiveness.
- Future Drawdowns: Up to $7,500,000 additional principal available in tranches of $2,500,000 every three months, purchasable at 90% of principal ($2,250,000 per tranche).
- Interest Rate: 4% annually, increasing to 14% upon an Event of Default.
- Repayment Terms: Ten equal monthly installments beginning on the 18th month anniversary of issuance, unless repaid earlier or extended.
- Conversion Terms: Convertible at the holder's option at the lower of $1.01 or 12% of the 20-day VWAP, subject to a floor price of $0.20 per share.
- Use of Proceeds: Working capital, general corporate purposes, and potential strategic acquisitions.
Material Changes
The filing represents a significant change in the company's capital structure through the introduction of debt instruments with equity conversion features. Unlike prior periods, the company now has a committed facility for up to $10 million in convertible debt, subject to specific volume-based conditions for the final tranches.
Guidance, Outlook, and Risks
- Management Commentary: The company intends to use proceeds to support strategic opportunities and working capital needs.
- Contingencies: Future issuance of notes beyond the second closing is contingent on the company's discretion and, for certain tranches, daily trading volume reaching 150% of outstanding shares.
- Risks: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially from expectations. The notes are subject to dilution upon conversion, capped at 4.99% beneficial ownership per holder.
- Unusual Items: The notes are issued at a discount (90% of principal) and carry a significant interest rate penalty (14%) upon default.
Investor Verification Checklist
- Verify the effectiveness date of the Registration Statement required for the Second Initial Closing.
- Confirm the current daily trading volume relative to outstanding shares to assess eligibility for volume-triggered note purchases.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for specific default triggers and adjustment mechanisms.
- Assess the potential dilution impact given the conversion price floor of $0.20 and the 12% VWAP discount.
- Check subsequent filings for any updates on the utilization of the remaining $7,500,000 subscription amount.